Welcome to the latest edition of touchREVIEWS in Oncology & Haematology!
This edition explores the role of new agents and combination therapies in the treatment of non-metastatic castration-resistant prostate cancer, metastatic and recurrent cervical cancer, Waldenstrom’s macroglobulinemia, immunoglobin light chain amyloidosis and paroxysmal nocturnal haemoglobinuria. Immunotherapy has transformed the treatment of numerous solid tumours and haematological malignancies. This issue has a particular focus on new immune checkpoint inhibitors in multiple myeloma, advanced melanoma and metastatic triple-negative breast cancer.
We conclude with a case report, in which Abdeljelil et al. highlight the use of haplo-identical haematopoietic stem-cell transplantation in refractory Hodgkin lymphoma after a carmustine, etoposide, cytarabine and melphalan (BEAM) conditioning regimen.
We would like to thank our contributors for producing insightful and informative articles.
Enjoy and happy reading!
Foreword – touchREVIEWS in Oncology & Haematology – VOLUME 17 ISSUE 2 – 2021
Welcome to the winter edition of touchREVIEWS in Oncology & Haematology. Despite the continued impact of the COVID-19 pandemic on cancer care, 2021 has seen important advances in many areas of oncology, which is reflected in our diverse range of articles. We begin with one of our popular expert interviews, in which Axel Merseburger discusses the […]
The Future of Advanced Prostate Cancer Treatment
Prostate cancer is one of the leading causes of cancer death worldwide.1 However, the emergence of novel hormonal therapies and the increasing availability of sensitive next-generation imaging techniques, such as gallium-88 prostate-specific membrane antigen (PSMA)-targeted positron emission tomography (PET), has transformed the management of advanced prostate cancer. Numerous agents, including abiraterone, enzalutamide, apalutamide, darolutamide, docetaxel, cabazitaxel, […]
Lymphocyte-activation Gene 3 and Programmed Cell Death 1 Checkpoint Inhibition as a Novel Combination in Advanced Melanoma
RELATIVITY-047 reported on the initial efficacy and safety of relatlimab (RELA), an antibody to lymphocyte-activating gene 3 (LAG-3), in combination with nivolumab (NIVO), an antibody to programmed cell death 1 (PD-1).1 These positive findings add to the existing evidence for the efficacy of anti-PD-1 therapy – either alone or in combination with ipilimumab (IPI), an antibody […]
A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer
Cumulatively, TNBC accounts for 35–40% of breast cancer deaths in the United States, despite only comprising 10–15% of total breast cancer cases diagnosed.1 Even before the use of anti-estrogen therapies became widespread, hormone receptor-positive breast cancer (HR+BC) provided a far more favourable risk of recurrence and overall prognosis compared with TNBC.2,3 Once metastatic, TNBC historically carries […]
Tisotumab Vedotin in Cervical Cancer: Current Status and Future Perspectives
Cervical cancer (CC) is the fourth most common female malignancy, with 640,127 new cases and 341,831 deaths in 2020 worldwide. Despite the introduction of screening programmes and vaccination campaigns, CC still represents one of the leading causes of cancer-related death in women.1 The appropriate treatment strategy is determined according to the stage of disease at […]
Bruton’s Tyrosine Kinase Inhibitors for the Treatment of Waldenström’s Macroglobulinaemia: A Canadian Perspective
Current treatment landscape in Canada Waldenström’s macroglobulinaemia (WM) is a rare haematological disorder with an incidence of about three cases per million, leading to approximately 150 new cases per year in Canada.1,2 WM is characterized by a clonal lymphoplasmacytic infiltration of the bone marrow and the presence of an IgM monoclonal protein.3,4 Symptomatic disease can arise from […]
Daratumumab for Immunoglobulin Light Chain Amyloidosis
Immunoglobulin light chain (AL) amyloidosis is the most common type of systemic amyloidosis, a spectrum of diseases induced by misfolded proteins that generate insoluble amyloid fibrils and deposits in various organs. The precursor protein in AL amyloidosis is a toxic, free light chain (FLC) secreted by an indolent plasma cell or B-cell clone in the […]
Pegcetacoplan in Paroxysmal Nocturnal Haemoglobinuria
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, chronic haematological illness. The condition presents on a background of bone marrow failure, and affected individuals can experience an array of symptoms due to chronic haemolysis, as well as episodes of acute haemolysis and thrombotic events.1 Diagnostic delays in PNH are common as not all patients experience classical symptoms, […]
New Checkpoint Inhibitors and Immunotherapies for Solid Tumours
The antitumor activity of immune checkpoint inhibotors in various solid and haematologic malignancies has substantially increased immunotherapy implications for cancer. Once only a niche treatment for selected cancers (renal cancer and melanoma), now cancer immunotherapy has become an important option for many patients, even moving into the first-line systemic treatment setting for melanoma, non-small cell […]
The Anti-CD19 Antibody–Drug Conjugate Loncastuximab Tesirine
The addition of rituximab to chemotherapy provides an overall survival benefit in aggressive lymphomas,1 whereas for indolent lymphoma subtypes this addition has resulted in improvements in progression-free survival.2 For more than two decades, immunotherapy with monoclonal ‘naked’ antibodies targeting CD20 remained the primary representative of this therapeutic modality,3 with a small number of patients receiving anti-CD20 radioimmunotherapy.4 A […]
Melphalan Flufenamide: a Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
Multiple myeloma (MM) is the second most common haematological malignancy, affecting an estimated 450,600 patients worldwide, with an estimated 34,920 new diagnoses and 12,410 patient deaths in the USA in 2021.1,2 Although established curative therapies for MM have not yet been defined, we have observed an incremental increase in survival, with a doubling of 5-year survival […]
New and Emerging Therapeutics for Non-metastatic Castrate-resistant Prostate Cancer
The American Cancer Society estimates that approximately 248,530 new cases of prostate cancer will be diagnosed in the United States in 2021.1 For the nearly 90% of patients diagnosed with locoregional prostate cancer, the goal of treatment by surgical intervention or radiation is cure. In some cases, active surveillance is appropriate. For locoregional prostate cancers, these […]
Haplo-identical Haematopoietic Stem Cell Transplantation in Refractory Hodgkin Lymphoma After Carmustine, Etoposide, Cytarabine, Melphalan Conditioning Regimen
Allogeneic haematopoietic stem cell transplant (allo-HSCT) remains a potential curative therapeutic option for patients with refractory/relapsed Hodgkin lymphoma (HL) in whom an autologous peripheral blood stem-cell transplantation (PBSCT) has failed. This is explained by the additional benefit of a graft-versus-lymphoma (GVL) effect. Unfortunately, HLA-identical donors are not available for all patients. In such cases, haplo-identical […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!